Gregg Gilbert Recent News
Does Reward Potential Still Outweigh The Risk In Akorn Shares?
Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers
What The Copaxone Court Ruling Means For Teva Pharmaceuticals
Amid Exec Departure, Teva's 2017 Outlook Now More Important Than Ever
Deutsche Tweaking Its Mylan View Following CEO's Congressional Testimony
Recent Patent Ruling A Positive For Pfizer
Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report
Deutsche Thinks Perrigo's Lowered Expectations Are Beatable
Deutsche Analysts React To Bristol-Myers Clinical Trial Disappointment
Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging
A Fairly Balanced Risk And Reward Scenario For Lannett; Deutsche Bank Initiates At Hold
Is Allergan Worth Over $300 Without Pfizer?
Deutsche Bank: Valeant Stock Could Be Worth $18, $30 Or $36
Deutsche Bank Suspends Valeant Rating, Says It Was 'Long Skeptical' Of Business Model
Jazz Pharma Falls After Q4 Sales Miss Street View
Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought
Here's Why Valeant Is Worrying Deutsche Bank And Morgan Stanley
Endo Bought Par In One Of Biggest Generics M&A Deals Ever: What The Street's Saying
How Teva Grows 'After The Cliff'
Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma
Deutsche Bank Cuts Ligand Pharma To Hold
Deutsche Bank Boosts Mylan's Price Target On This Scenario
Akorn Initiated At Deutsche Bank, Notes Impressive Drug Pipeline